Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 05/08/25
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA CongressPRNewsWire • 04/28/25
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025PRNewsWire • 04/24/25
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual MeetingPRNewsWire • 04/07/25
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of NeurologyPRNewsWire • 03/27/25
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/26/25
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial ResultsPRNewsWire • 02/26/25
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025PRNewsWire • 02/12/25
Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/27/25
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferencePRNewsWire • 12/17/24
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/12/24
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/13/24
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder ValuePRNewsWire • 11/12/24
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and TheravanceZacks Investment Research • 11/11/24
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024PRNewsWire • 10/24/24
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseasePRNewsWire • 10/18/24
Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped24/7 Wall Street • 09/29/24
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/04/24